美国HIV感染者中脂肪性肝病、MASLD、MetALD及显著纤维化的患病率
本研究前瞻性纳入美国9个中心的1065例HIV感染者,评估新命名下脂肪性肝病各分类的患病率及相关因素。结果显示SLD患病率52%、MASLD 39%、MetALD 10%、显著纤维化15%、进展期纤维化4%;肥胖、ALT和AST与MASLD及显著纤维化风险增加相关,黑人种族具有保护作用。
要点
- HIV感染者中MASLD和MetALD是SLD的主要病因,合计影响近半数患者。
- SLD患病率52%,MASLD 39%,MetALD 10%,显著纤维化15%,进展期纤维化4%。
- 肥胖、ALT和AST水平与MASLD及显著纤维化风险增加相关,黑人种族具有保护作用。
核心结论
- MASLD和MetALD是HIV感染者中SLD的主要病因,影响近半数患者;应用新命名后,原本可诊断为NAFLD的患者中MASLD比例变化极小。
研究设计与样本
- 前瞻性研究,从美国9个中心纳入1065例HIV感染者,进行临床评估和振动控制瞬时弹性成像检测受控衰减参数(CAP)和肝硬度值(LSM)。
主要发现
- SLD患病率为52%,MASLD为39%,MetALD为10%,ALD为3%,显著纤维化为15%,进展期纤维化为4%,隐源性SLD仅0.6%。
- 黑人种族与MASLD和显著纤维化风险降低相关,肥胖、ALT和AST水平与MASLD和显著纤维化风险增加相关。
- HIV或抗逆转录病毒治疗不影响MASLD风险。
关键数值与推荐
- SLD定义为CAP≥263 dB/m,显著纤维化定义为LSM≥8 kPa,进展期纤维化定义为LSM≥12 kPa。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD. AIMS: To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF). METHODS: PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration-controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa. The prevalence of SLD, MASLD, metabolic dysfunction and alcohol-associated liver disease (MetALD), ALD, cryptogenic (cSLD), CSF and AF were determined. Uni- and multivariate logistic regression models were used to assess factors associated with MASLD and CSF risk. RESULTS: Of 1065 participants, 74% were male, mean (SD) age 51.6 ± 11.9 years, 46% non-Hispanic Black and 74% with undetectable HIV RNA. The prevalence of SLD was 52%, MASLD 39%, MetALD 10%, ALD 3%, CSF 15% and AF 4%. Only 0.6% had cSLD. Black race was protective whereas obesity, ALT and AST levels were associated with increased risk of MASLD and CSF in MASLD. HIV or antiretroviral therapy did not affect MASLD risk. CONCLUSIONS: MASLD and MetALD are the dominant causes of SLD in PWH, affecting almost half. Application of the new nomenclature resulted in minimal change in the proportion of patients with MASLD who would have been diagnosed previously with NAFLD.
引用
- Gawrieh S, Vilar-Gomez E, Woreta TA, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment Pharmacol Ther. 2023. PMID: 38158589. doi:10.1111/apt.17849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。